Clinical trials: SARS-COV2 Virus
Coronavirus, COVID
Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France
Arriving in December 2019, Coronavirus COVID-19 infection is causing a global pandemic with high morbidity and mortality among adults and especially seniors. The child appears little or no affected by this infection.
- Conditions
- Coronavirus, COVID, Infection Viral
- Trial name
- INCOVPED (NCT04336761)
- Testing
- nasopharyngeal swab
- Where
- 6 sites in France
- Volunteers
- 901 people
- Sponsor
- University Hospital, Lille
Coronavirus Infections
A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
This proof of concept study will take place in the US and other countries in approximately 15 clinical sites and will enroll about 40 hospitalized patients diagnosed with COVID-19 infection who have developed pneumonia and…
- Trial name
- COVID-19 (NCT04414618)
- Testing
- Opaganib
- Where
- 9 sites in United States, Israel
- Volunteers
- 42 people
- Sponsor
- RedHill Biopharma Limited
Anosmia, Asymptomatic COVID-19
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
The purpose of this study is to learn more about how to better track smell recovery in people who have been infected with the SARS-CoV-2 virus (which causes COVID-19).
- Conditions
- Anosmia, Asymptomatic COVID-19, COVID-19 Respiratory Infection, Influenza
- Trial name
- NCT05040659
- Testing
- AROMHA Longitudinal Smell Test
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
SARS-CoV2 Infection
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
The primary objective of this study is to provide expanded access of remdesivir (RDV) for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.
- Trial name
- NCT04323761
- Testing
- Remdesivir
- Where
- 272 sites in United States, Australia and 25 more
- Sponsor
- Gilead Sciences
SARS-CoV2 Infection, COVID-19
Viral Dynamics of Omicron in Children
SARS-CoV-2 transmission is dependent on multiple factors, which may be related to either host-virus interaction or the environment.
- Trial name
- NCT05240183
- Testing
- Daily SARS-CoV-2 PCR Testing for 10 days
- Where
- Canada
- Volunteers
- 107 people
- Sponsor
- The Hospital for Sick Children
Paediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-Cov-2
Paediatric Inflammatory Multisystem Syndrome During COVID-19 Pandemic
During the COVID-19 pandemic, a small minority of children have been presenting to acute paediatric services with a new syndrome, Paediatric Inflammatory Multisystem Syndrome temporally associated with SARS-Cov-2 (PIMS-TS).
- Trial name
- NCT04761913
- Where
- 6 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Anglia Ruskin University
SARS-CoV-2 Infection
Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine
This study aims to address evidence gaps regarding the safety, reactogenicity and immune responses of a heterologous boost of a single dose of Ad26.COV2.S (half or full dose) at pre-specified time intervals in recipients who are…
- Trial name
- NCT05109559
- Testing
- Full dose of Ad26.COV2. 5x10^10vp, Half dose of Ad26.COV2. 2.5x10^10vp
- Where
- Thailand
- Volunteers
- 690 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Covid19
Covid-19 Rapid Diagnostic Tests on Blood Drop
This study will evaluate the diagnostic reliability of the Biosynex rapid blood test for Covid-19 infection.
- Trial name
- COVID-TEST (NCT04467008)
- Where
- France
- Volunteers
- 113 people
- Sponsor
- CMC Ambroise Paré
COVID-19, SARS-CoV-2 Infection
Evaluation of the Efficacy and Safety of Molnupiravir Treatment in Mild/Moderate Covid-19 Patients.
Evaluation of the Efficacy and Safety of Molnupiravir Treatment in Mild/Moderate Covid-19 Patients. Turkey Cohort, Prospective, Observational, Comparative Study In the antiviral treatment of COVID-19, molnupiravir, an RdRp…
- Trial name
- NCT06223932
- Testing
- Molnupiravir
- Where
- 8 sites in Turkey (Türkiye)
- Volunteers
- 2,600 people
- Sponsor
- Serap Yavuz
Covid19, SARS-CoV-2
Changes in Cellular Immune Profile During COVID-19 Infection
Clinical specimens are collected from individuals either recovered from or with active SARS-CoV-2 infection to support process and analytical development for a potential cell-based immunotherapy in preclinical research…
- Trial name
- NCT04470999
- Testing
- Leukapheresis
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Serhat Gumrukcu, MD PhD
COVID-19 (SARS-CoV-2 Infection)
Use of a Cysteine-rich Whey Protein Isolate in Post COVID-19 Cognitive Impairment
Abstract Background: Post-COVID-19 cognitive impairment (PCCI), characterized by deficits in attention, memory, and executive functioning, remains a major challenge among patients with long COVID.
- Trial name
- NCT07184398
- Testing
- Intervention with Consolidated Cysteine (Immunocal) 20 g per day, Cognitive rehabilitation workshops
- Where
- Colombia
- Volunteers
- 120 people
- Sponsor
- Universidad Libre seccional Cali
COVID-19 Infections
Monitoring the IgG/IgM Antibodies in COVID-19 Patients
The COVID-19 was declared a global pandemic by WHO more than a year ago, and the world is still experiencing a state of global emergency.
- Trial name
- NCT04810117
- Testing
- Serodiagnosis of IgG and IgM
- Where
- 2 sites in Pakistan
- Volunteers
- 373 people
- Sponsor
- University of Sargodha
Covid19
Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection
This study proposes to evaluate the therapeutic efficacy, immunologic effects and normalization of laboratory parameters for patients at high risk for mortality when infected by SARS-CoV-2 (COVID-19) when administered one unit…
- Trial name
- NCT04513158
- Testing
- Convalescent Plasma
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Joseph M. Flynn, D.O., MPH
SARS CoV 2 Infection, Vaccination Reaction
Evaluation of Post-vaccination Anti-SARS-CoV-2 Serological Response in Health Care Workers With a History of COVID-19.
Since the beginning of 2020, a major pandemic due to the new emerging coronavirus (SARS-CoV-2) has been spreading around the world.
- Trial name
- VACCICOVID (NCT04934215)
- Where
- France
- Volunteers
- 73 people
- Sponsor
- Fondation Hôpital Saint-Joseph
COVID-19, COVID Long-Haul
Comprehensive Imaging Exam of Convalesced COVID-19 Patients
COVID-19 is a systemic inflammatory disease involving many organs including the lungs, vascular system liver and myocardium that lead to severe pathologies.
- Trial name
- NCT05920616
- Testing
- Magnetic Resonance Imaging, Ultra-High Resolution Computed Tomography (CT) Scan
- Where
- United States
- Volunteers
- 206 people
- Sponsor
- Johns Hopkins University
Solid Organ Transplant Recipients, Autoimmune Diseases
Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies
DESIGN Observational epidemiological study AIMS - To determine: 1. The proportion of immunosuppressed people who have detectable SARS-CoV-2 antibodies following a primary vaccine course (3 doses), and the demographic, disease…
- Conditions
- Solid Organ Transplant Recipients, Autoimmune Diseases, Haematological Malignancies
- Trial name
- MELODY (NCT05148806)
- Testing
- self-administered lateral flow assays
- Where
- 4 sites in United Kingdom
- Volunteers
- 28,411 people
- Sponsor
- Imperial College London
Covid19
Post-COVID-Health Study: Multidimensional Health Status of COVID-19 Survivors One Year After a SARS-CoV-2 Infection
This study assesses the multidimensional health status of COVID-19 survivors one-year post-infection using validated subjective and objective measures.
- Trial name
- NCT04794985
- Where
- 3 sites in Netherlands
- Volunteers
- 140 people
- Sponsor
- Maastricht University Medical Center
Coronavirus Infections
French COVID Cohort
Infectious disease is the single biggest cause of death worldwide. New infectious agents, such as the SARS, MERS and other novel coronavirus, novel influenza viruses, viruses causing viral haemorrhagic fever (e.g.
- Trial name
- FrenchCOVID (NCT04262921)
- Where
- 98 sites in France
- Volunteers
- 4,415 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
COVID 19, SARS-CoV 2
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe…
- Conditions
- COVID 19, SARS-CoV 2, Pneumonia
- Trial name
- NCT04492514
- Testing
- Mavrilimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Kristin Hudock
COVID 19 Disease
Tafenoquine in Patients With Mild to Moderate COVID-19
A clinical study to assess the efficacy and safety of oral tafenoquine compared to placebo in patients with mild to moderate COVID 19 disease.
- Trial name
- NCT04533347
- Testing
- Tafenoquine Oral Tablet
- Where
- 10 sites in United States
- Volunteers
- 86 people
- Sponsor
- 60 Degrees Pharmaceuticals LLC